he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源IP
- 2022-05-05青少年癫痫病因有哪些
- 2022-05-022013年国际抗癫痫联合会抗癫痫药物使用指南
- 2022-04-25病故中后癫痫首选用药有哪些?解答病故中后癫痫的4大问题
- 2022-04-13治疗类风湿性关节炎/膝骨关节炎的专家共识
- 2022-04-12如何治疗弱精不育症?
- 2022-04-11泰国试管婴儿成本比中国高的原因是什么?
- 如何治疗弱精不育症?
- 泰国试管婴儿成本比中国高的原因是什么?
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 癫痫治疗障碍仍难以克服
- 综述:癫痫持续状态诊治最新进展
- 2013国际抗癫痫联合会抗癫痫药用指南
- 预测癫痫患者再入院风险
- 抗癫痫药物预防新发癫痫:任重而道远
- UCB的Vimpat癫痫新适应症在美国获批
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 北京癫痫手术费用
- 特发性癫痫大发作药物治疗的首选
- 癫痫患者手术评估新型工具
- 癫痫病的最新治疗方法 癫痫发作的急救
- 三庚酸酯可治疗1型转运体缺陷综合征
- 癫痫治愈费用
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- 控制癫痫患者再次抽搐,不包括可选药物?
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- FDA警告怀孕期间使用丙戊酸钠药物
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 月经性癫痫患者妊娠期癫痫控制更好
- 2015 神经系统疾病诊疗进展
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 上海率先探索异地就医门诊费直接结算
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 怎样标记癫痫病的早期征兆
- 最理论上治疗癫痫病的药是哪些
- 兴癫痫病能兴的好么
- 中科西部干细胞研究院:干细胞治疗脑出血后遗症全国性有新药了!
- 人类记忆究竟如何形成及提取?历年来最清晰证据出现!
- 癫痫的治疗法 治疗法癫痫的偏方大全
- 初步推测急性脑炎死亡的预测因素
- 罕见病症:自发性颞极膨出伴癫痫发作
- 激起癫痫病发作的因素有哪些
- 癫痫病是什么症状及治疗作法
- 产妇癫痫病怎么治疗
- 什么是局灶性发作?局灶性发作的治疗
- 放射治疗癫痫病药品要怎么放射治疗好啊